image credit- shutterstock
Mumbai-based JB Pharma has entered into an agreement with Glenmark Pharmaceuticals to acquire the entire Razel (Rosuvastatin) franchise for the India and Nepal region for Rs 314 crore.
With this acquisition, JB Pharma will complete its cardiac portfolio making it a leader in this segment, as Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country.
These brands are focused on the cardiac segment in India and Nepal with a total covered market size of Rs 2,444 crore as per IQVIA MAT Oct '22 numbers.
Commenting on the acquisition, Nikhil Chopra, CEO & Whole Time Director, JB Pharma said, “With this addition, we now have established a strong position in statins besides being among the leaders in Hypertension and Heart failure – all the fastest growing therapeutic indications in cardiology.”
He further added, “We see good growth potential from the acquired brands. This acquisition will help us leverage our existing Go-To-Market model focused for this segment and further strengthen our chronic portfolio.”
